Current financial headlines
Sharemaestro Newsreel
Financial news from across the world, newest first. Choose a country or market group, open the source, or continue into the company data.
- Showing
- 217–252
- Headlines
- 36528
- Sources here
- 14
- Companies here
- 31
Chronological news
Earlier headlines
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Why Did Oscar Health (OSCR) Fall After Record Profit and a Guidance Hike?
Oscar Health, Inc. (NYSE:OSCR) shares closed 11.9% lower at $26.54 on August 6, even after the insurer reported its most profitable first half and raised its full-year outlook. Second-quarter revenue rose 70% year over year to $4.88 billion, while the company swung to net …
Trinity Biotech Secures Additional $7.0 Million Investment from Perceptive Advisors and Regains Compliance with Nasdaq Minimum Bid Price Requirement
Trinity Biotech (NASDAQ: TRIB) has secured an additional $7.0 million investment from Perceptive Advisors, its largest financial investor, and has regained compliance with Nasdaq's minimum bid price requirement. The investment, consisting of new debt funding and capitalized interest, aims to bolster liquidity for strategic …
Tenet Healthcare Corporation (THC) Hits Fresh High: Is There Still Room to Run?
Shares of Tenet Healthcare (THC) have been strong performers lately, with the stock up 34.1% over the past month. The stock hit a new 52-week high of $270.57 in the previous session. Tenet has gained 34.4% since the start of the year compared to …
Is BioMarin Pharmaceutical (BMRN) Outperforming Other Medical Stocks This Year?
BioMarin Pharmaceutical (BMRN) is outperforming the Medical sector and its specific industry year-to-date, with a 15.3% return compared to the sector's 3%. The company holds a Zacks Rank #2 (Buy) due to improving analyst sentiment. Cardinal Health (CAH) is another medical stock showing strong …
Attention Long-Term Shareholders of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY); Bloom Energy Corporation (NYSE: BE); Erasca, Inc. (NASDAQ: ERAS); and Insulet Corporation (NASDAQ: PODD): Grabar Law Office is Investigating Claims on Your Behalf
Grabar Law Office is investigating potential breaches of fiduciary duty by officers and directors of ARS Pharmaceuticals, Inc., Bloom Energy Corporation, Erasca, Inc., and Insulet Corporation. The investigations concern various allegations including misleading statements regarding product timelines, supply chain reliance, and manufacturing issues, which …
PDS Biotechnology shareholders approve charter amendment and director elections
PDS Biotechnology Corporation shareholders have approved an amendment to the company's certificate of incorporation, increasing the number of authorized common shares from 150 million to 300 million. They also elected two Class B directors, Kamil Ali-Jackson and Ilian Iliev, and ratified KPMG US LLP …
Twist Bioscience (TWST): EdgePoint discloses 4.21% beneficial stake in amended 13G
EdgePoint Investment Group Inc. has filed an amended Schedule 13G, disclosing a 4.21% beneficial ownership stake in Twist Bioscience Corp (TWST), totaling 2,521,635 shares as of June 30, 2026. The filing indicates EdgePoint acts as an investment manager for various funds that directly own …
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Bicara Therapeutics Inc. announced an inducement grant to Jennifer Larson, its new Chief Financial Officer, effective August 12, 2026. Ms. Larson received a non-qualified stock option to purchase 285,000 shares of common stock at an exercise price of $24.63 per share, vesting over approximately …
Form 8K TuHURA Biosciences Inc For: 14 August By Investing.com
This article reports that TuHURA Biosciences Inc. filed a Form 8K on August 14. The filing is brief and does not contain additional details within the provided content. It is published by Investing.com, a financial markets news platform.
Anteris Technologies Global (NASDAQ:AVR) Earns Overweight Rating from Cantor Fitzgerald
Cantor Fitzgerald reiterated an "overweight" rating on Anteris Technologies Global (NASDAQ: AVR) with a $15 price target, suggesting a significant upside. Despite weaker-than-expected quarterly results and insider selling, the stock maintains a "Moderate Buy" consensus rating from analysts. The company's stock has shown some …
Insider Spends US$141k Buying More Shares In Embecta
Embecta's President, Devdatt Kurdikar, recently purchased US$141k worth of company stock at US$4.70 per share, increasing his holding by 3.9%. This is the largest insider purchase in the last year, suggesting optimism for the company's future, despite the overall insider ownership being relatively low …
Embecta Corp. SVP Elguicze purchases $93,360 in common stock
Embecta Corp.'s Senior Vice President and CFO, Jacob Elguicze, recently purchased 20,000 shares of the company's common stock for $93,360. This insider purchase comes after a significant stock decline but a recent rebound, with the company trading at a low P/E ratio. The purchase …
Sirenia Capital (HELP) reports 3.03M-share Cybin stake including warrant shares
Sirenia Capital Management LP and Alex Silverstein have reported a beneficial ownership of 3,029,500 Common Shares in Cybin Inc., which includes 969,500 shares issuable upon the exercise of warrants. This stake represents 4.8% of Cybin's outstanding Common Shares, based on 61,984,078 shares as of …
Delcath Systems updates bylaws to designate Delaware courts as exclusive forum
Delcath Systems, Inc. (NASDAQ:DCTH) has amended its bylaws to designate Delaware courts as the exclusive forum for internal corporate claims and federal district courts for claims under the Securities Act of 1933. This decision follows a recommendation from its Nominating and Corporate Governance Committee. …
Form 8K Delcath Systems Inc For: 14 August By Investing.com
This article announces the filing of a Form 8K by Delcath Systems Inc. on August 14th. It is a brief news item from Investing.com, providing basic information about the regulatory filing.
Vivos to discuss collaborations’ anticipated effect on revenue growth and cash burn
Vivos Therapeutics (NASDAQ: VVOS) will release its second quarter 2026 financial results after market close on Friday, August 14, 2026, and will host a conference call at 5:00 p.m. Eastern Time. Management plans to discuss strategic collaborations and their anticipated effect on near-term revenue …
Vistagen reports Q1 FY2027: $1.48M revenue, $13.0M net loss, $31.7M cash at June 30, 2026
Vistagen announced its Q1 FY2027 results, reporting $1.476 million in revenue and a net loss of $13.03 million. The company ended the quarter with $31.7 million in cash, expecting these funds to support operations into 2027. Vistagen also highlighted upcoming FDA discussions regarding a …
Form 8K VistaGen Therapeutics Inc For: 14 August By Investing.com
This article announces that VistaGen Therapeutics Inc. has filed a Form 8K on August 14th. The brief news item from Investing.com provides no further details about the content of the filing but notes the stock symbol VTGN.